Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 532 • 2017 ACR/ARHP Annual Meeting
Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis
Wenjing Xiao, Department of Rheumatology and Immunology, People’s Hospital, , Peking University, Beijing, Beijing, China
Background/Purpose: Iguratimod (IGU) is a novel DMARD in rheumatoid arthritis (RA). The purpose of this study was to identify genetic predictors of response and adverse…
Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting
Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Christian Secchi^1,2,3, Karen M. Doody², Mattias N. D. Svensson^2,4, Frances Humby⁵, Rebecca Hands⁵, Eugenio Santelli^1,2, Cristiano Sacchetti^2,6, Kuninobu Wakabayashi⁷, Dennis J. Wu⁸, Ardita Aliko⁹, Piotr Mydel^9,10, Tsuyoshi Kasama⁷, David L. Boyle¹¹, Francesco Galimi¹², Michel L. Tremblay¹³, Gary S. Firestein⁶, Costantino Pitzalis⁵, Stephanie Standford^8,14 and Nunzio Bottini^2,4, ¹Medicine, University of California San Diego, San Diego, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Medicine, National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁶Medicine, University of California San Diego, La Jolla, CA, ⁷Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ⁸University of California San Diego, San Diego, CA, ⁹University of Bergen, Bergen, Norway, ¹⁰Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ¹¹University of California San Diego, La Jolla, CA, ¹²National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, ¹³Goodman Cancer Centre, McGill University, Montréal, QC, Canada, ¹⁴La Jolla Institute for Allergy and Immunology, La Jolla, CA
Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…
Abstract Number: 2471 • 2017 ACR/ARHP Annual Meeting
Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Roy Fleischmann¹, Greg St. John², Toshio Kimura², Melitza Iglesias-Rodriguez³, Itzhak Rosner⁴ and Gerd R. Burmester⁵, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Cambridge, MA, ⁴Bnai-Zion Medical Center, Haifa, Israel, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously [SC] every 2…
Abstract Number: 241 • 2017 ACR/ARHP Annual Meeting
Histological and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained By Ultrasound Guided Biopsy in Phase 1 of the Accelerating Medicines Partnership RA Network
Andrew Filer¹, Arthur M. Mandelin II², Edward F. DiCarlo³, Brendan Boyce⁴, Darren Tabechian⁵, Ralf G. Thiele⁶, Stephan Kelly⁷, Ellen M. Gravallese⁸, Diane Horowitz⁹, Kevin Wei¹⁰, Deepak Rao¹¹, Vivian P. Bykerk¹² and Jennifer H. Anolik¹³, ¹Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Northwestern University, Chicago, IL, ³Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Queen Mary University of London, London, United Kingdom, ⁸Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA, ⁹Division of Rheumatology, North Shore - Long Island Jewish Health System, Woodbury, NY, ¹⁰Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Spring, IN, ¹²2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹³Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The AMP-RA network applies cutting edge technologies to the study of tissue obtained by ultrasound guided synovial biopsy from patients with rheumatoid arthritis (RA).…
Abstract Number: 547 • 2017 ACR/ARHP Annual Meeting
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Diederik De Cock¹, Lianne Kearsley-Fleet¹, Lucía Silva Fernández², Mark Lunt¹, Kath Watson¹, Deborah P.M. Symmons^1,3 and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX) or a second tumour necrosis factor inhibitor (TNFi) are both permitted treatment options for patients with rheumatoid…
Abstract Number: 1739 • 2017 ACR/ARHP Annual Meeting
Vδ1, Vδ2, and Other γδT Cells in Blood and Synovium of Rheumatoid Arthritis and Other Autoimmune Arthritides
Anna Helena Jonsson¹, Michael Gurish¹, Lauren Henderson², Peter Nigrovic¹ and Michael Brenner³, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Innate-like T cells comprise on average 10-15% of peripheral T cell and have T-cell receptors (TCRs) that engage ligands other than classic HLA class…
Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James T. Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵ and Rita Tarzynski-Potempa⁵, ¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
Abstract Number: 336 • 2017 ACR/ARHP Annual Meeting
Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control
Maria I. Danila¹, Eric M. Ruderman², Leslie R Harrold³, Joshua A. Melnick¹, Ronan O'Beirne¹, Monika M. Safford⁴, Joel Kremer⁵ and Jeffrey R. Curtis⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Massachusetts Medical School, Worcester, MA, ⁴Weill Cornell Medical College, New York, NY, ⁵Corrona, LLC, Southborough, MA, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many patients with RA do not achieve guideline-recommended treat-to-target (T2T) goals in clinical practice. There is a paucity of data regarding the challenges that…
Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Shalini Mohan¹, Margaret Michalska², Jeffrey Yourish², Jinglan Pei², Sara Gale¹, Christine Birchwood² and Erhan Berber², ¹Genentech, South San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…
Abstract Number: 1816 • 2017 ACR/ARHP Annual Meeting
Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Michael Richter¹, Cynthia S. Crowson², Eric L. Matteson³ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Despite a decline in the incidence of orthopedic surgeries for rheumatoid arthritis (RA) in recent years, joint replacement remains an option for patients with…
Abstract Number: 2482 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Gerd R. Burmester¹, Stefano Fiore², Chih-Chi Hu³, Jonathan Fay⁴, Eun Bong Lee⁵ and Mark C. Genovese⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgwater, NJ, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁶Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy and safety of sarilumab as monotherapy and combination therapy have been reported.1-3 In MONARCH (NCT02332590),…
Abstract Number: 388 • 2017 ACR/ARHP Annual Meeting
Induction of Anti-Citrullinated Protein Antibodies By Peptidyl Arginine Deiminase Immunization: A New Model for the Development of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
Fanny Arnoux^1,2, Nathalie Lambert^1,3, Nathalie Balandraud^1,2,4, Jean Roudier^1,3,5 and Isabelle Auger^1,2, ¹Aix Marseille University, Marseille, France, ²INSERM UMRs 1097, Marseille, France, ³Arthrites auto-immunes, INSERM UMRs 1097, Marseille, France, ⁴APHM, Marseille, France, ⁵Rheumatology dept, APHM, Marseille, France
Background/Purpose: The most important immunological event in rheumatoid arthritis (RA) is the development of anti-citrullinated protein autoantibodies (ACPAs). ACPAs are present in 2/3 of patients.…
Abstract Number: 778 • 2017 ACR/ARHP Annual Meeting
Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
Sara Gale¹, Sophie Dimonaco², Huong Trinh¹, Katie Tuckwell², Neil Collinson², John H. Stone³, Khaled Sarsour¹, Jinglan Pei⁴, Jennifer H. Best¹, Christine Birchwood⁴ and Shalini Mohan¹, ¹Genentech, South San Francisco, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Recent clinical trial findings have shown efficacy for tocilizumab (TCZ) in treating giant cell arteritis (GCA).1,2 TCZ was approved for the treatment of GCA…
Abstract Number: 1970 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Rheumatoid Arthritis and Allergic Diseases and Their Association : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Sang Hyun Joo¹, Eun Hye Park², Joongyub Lee³ and Yeong Wook Song^2,4, ¹Division of Rheumatology, Department of Internal Medicine, Jungang Medical Foundation, Jeju, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ³Division of Clinical Epidemiology Medical Research Collaborating Center Biomedical Research Institution, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea., Seoul, Korea, Republic of (South)
Background/Purpose: Allergy and autoimmune disease are related to the immune system. It was not clear in the previous studies whether allergic disease (e.g., asthma, allergic…
Abstract Number: 2490 • 2017 ACR/ARHP Annual Meeting
Sustained Clinical Response in Refractory Rheumatoid Arthritis Patients with a Low-Dose Rituximab Retreatment Regimen. a Single Center Experience
Sebastian C Rodriguez-Garcia, Raul Castellanos-Moreira Sr., M. Victoria Hernández, Andrea Cuervo, Virginia Ruiz-Esquide, Julio Ramírez, Juan Cañete and Raimon Sanmartí, Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: : The standard dose of rituximab (RTX) in rheumatoid arthritis (RA) is two intravenous (iv) 1 g infusions, separated by two weeks. Recently, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].